PRECISION BIOLOGICS TO PRESENT AT IMMUNO 2024, LONDON, UK, APRIL 25 – 26, 2024

IMMUNO 2024, LONDON, UK, APRIL 25 – 26, 2024

Day 1: Track 1: Discovery & Development: Cell & Gene and Combination Therapies; Afternoon Break – 1-2-1 Meetings x 3, Posters: 3:10pm, and 4:30pm
Director-Level Panel Discussion: Advancing IO Partnerships 2024
Moderator: PHILIP ARLEN, Chief Executive Officer, Precision Biologics, Inc.
Panelist: Russell Lamontagne, CEO, Boston Immune Technologies and Therapeutics, Inc.
– Novel therapeutic approaches & collaborations in therapeutics development
– Collaboration in clinical trials
– Successful partnership strategies in IO

Day 1: Track 4: Myeloid and Stem Cells to Enhance the Development of Novel Therapeutics; Roundtable Discussion 3: Improving Clinical Outcomes of Current I-O Therapies, 4:50pm
Moderator: PHILIP ARLEN, Chief Executive Officer, Precision Biologics, Inc.

Day 2; Track 3: Innovation & Collaboration Track
Presentation 1: Preclinical/Clinical Development Of A Neo-Epitope Targeted Monoclonal Antibody For Cancer Therapy, 3:00pm
- Screening and identification of tumor specific monoclonal antibodies
- Functional testing and target identification of NEO-201 mab
- Mechanisms of action for NEO-201
- Clinical data and future plans